Biohaven licenses Kv7 epilepsy drug platform to SK Biopharmaceuticals in deal worth up to USD 795 million
BHVN•Biohaven licenses Kv7 platform to SK Biopharmaceuticals
- Biohaven licensed its Kv7 ion channel platform to SK Biopharmaceuticals under an exclusive worldwide agreement led by epilepsy candidate opakalim.
- Deal terms include up to USD 795 million in upfront and milestone payments tied to the Kv7 platform.
- Biohaven will receive USD 400 million in cash consideration, including USD 350 million at closing and USD 50 million in 2027.
- Additional economics include USD 150 million in development and regulatory milestones, and tiered U.S. royalties from mid-teens to low twenties.
- Opakalim is in Phase 2/3 for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026.
